Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Liposomal irinotecan + Veliparib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Liposomal irinotecan | Onivyde | PEP02|nal-IRI|MM-398|Irinotecan Sucrosofate | TOPO1 inhibitor 11 | Onivyde (liposomal irinotecan) comprises irinotecan encapsulated in liposomal nanoparticles, which may result in increased tumor growth inhibition (PMID: 23406728, PMID: 16540680, PMID: 29945562). Onivyde (liposomal irinotecan) in combination with chemotherapy is FDA-approved for use in patients with metastatic pancreatic adenocarcinoma (FDA.gov). |
| Veliparib | ABT-888 | PARP Inhibitor (Pan) 29 | Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02631733 | Phase I | Liposomal irinotecan + Veliparib | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors | Completed | USA | 0 |